

Claims:

1. A therapeutic agent for a keratoconjunctival disorder which comprises

5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl]thiazolidine-2,4-dione or a salt thereof as an active ingredient.

2. The therapeutic agent according to claim 1 wherein said keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis or filamentary keratitis.

3. The therapeutic agent according to claim 1 which is in the dosage form of an eye drop or an ophthalmic ointment.

4. A method for treating a keratoconjunctival disorder which comprises administering

5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy) benzyl]thiazolidine-2,4-dione or a salt thereof to a patient in a therapeutically effective amount.

5. The therapeutic method according to claim 4 wherein said keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis or filamentary keratitis.

6. The therapeutic method according to claim 4 wherein the administration is instillation of an eye drop or administration of an ophthalmic ointment.

7. Use of

5-[4-(6-methoxy-1-methyl-1H-benzimidazol-2-ylmethoxy)benzyl] thiazolidine-2, 4-dione or a salt thereof for manufacture of a therapeutic agent for a keratoconjunctival disorder.

8. Use according to claim 7 wherein said keratoconjunctival disorder is dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis or filamentary keratitis.

9. Use according to claim 7 wherein said therapeutic agent is in the dosage form of an eye drop or an ophthalmic ointment.